- Home
- NMRA vs FDMT Comparison
NMRA vs FDMT Comparison
Compare NMRA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- FDMT
- Stock Information
- Founded
- NMRA 2019
- FDMT 2013
- Country
- NMRA United States
- FDMT United States
- Employees
- NMRA N/A
- FDMT N/A
- Industry
- NMRA
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- FDMT Health Care
- Exchange
- NMRA Nasdaq
- FDMT Nasdaq
- Market Cap
- NMRA 234.5M
- FDMT 192.2M
- IPO Year
- NMRA 2023
- FDMT 2020
- Fundamental
- Price
- NMRA $2.08
- FDMT $4.41
- Analyst Decision
- NMRA Buy
- FDMT Buy
- Analyst Count
- NMRA 8
- FDMT 10
- Target Price
- NMRA $7.14
- FDMT $32.33
- AVG Volume (30 Days)
- NMRA 2.2M
- FDMT 276.3K
- Earning Date
- NMRA 08-06-2025
- FDMT 08-07-2025
- Dividend Yield
- NMRA N/A
- FDMT N/A
- EPS Growth
- NMRA N/A
- FDMT N/A
- EPS
- NMRA N/A
- FDMT N/A
- Revenue
- NMRA N/A
- FDMT $23,000.00
- Revenue This Year
- NMRA N/A
- FDMT $11,586.49
- Revenue Next Year
- NMRA N/A
- FDMT N/A
- P/E Ratio
- NMRA N/A
- FDMT N/A
- Revenue Growth
- NMRA N/A
- FDMT N/A
- 52 Week Low
- NMRA $0.61
- FDMT $2.24
- 52 Week High
- NMRA $17.19
- FDMT $18.14
- Technical
- Relative Strength Index (RSI)
- NMRA 70.06
- FDMT 52.88
- Support Level
- NMRA $1.70
- FDMT $4.27
- Resistance Level
- NMRA $2.85
- FDMT $4.75
- Average True Range (ATR)
- NMRA 0.32
- FDMT 0.24
- MACD
- NMRA 0.05
- FDMT -0.00
- Stochastic Oscillator
- NMRA 58.08
- FDMT 43.48
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.